JDRF T1D Fund LLC 4
4 · Pandion Therapeutics, Inc. · Filed Jul 21, 2020
Insider Transaction Report
Form 4
JDRF T1D Fund LLC
10% Owner
Transactions
- Conversion
Common Stock
2020-07-21+204,313→ 204,313 total - Conversion
Common Stock
2020-07-21+222,020→ 426,333 total - Conversion
Series A Prime Preferred Stock
2020-07-21−948,225→ 0 total→ Common Stock (204,313 underlying) - Conversion
Series B Preferred Stock
2020-07-21−1,132,170→ 0 total→ Common Stock (222,020 underlying)
Footnotes (2)
- [F1]The Series A Prime Preferred Stock converted into Common Stock on a 4.6410-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Prime Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date
- [F2]The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.